Open Access
ARTICLE
Alterations in Metabolites Associated with Hypoxemia in Neonates and Infants with Congenital Heart Disease
Evan Pagano1, Benjamin Frank1, James Jaggers2, Mark Twite3, Tracy T. Urban4, Jelena Klawitter2,#, Jesse Davidson1,#,*
1 University of Colorado, Department of Pediatrics, Aurora, CO 80045, USA
2 University of Colorado, Department of Surgery, Aurora, CO 80045, USA
3 University of Colorado, Department of Anesthesiology, Aurora, CO 80045, USA
4 Children’s Hospital Colorado Research Institute, Aurora, CO 80045, USA
# Dr. Klawitter and Dr. Davidson contributed equally to the senior authorship of this manuscript
* Corresponding Author: Jesse Davidson. Email:
Congenital Heart Disease 2020, 15(4), 251-265. https://doi.org/10.32604/CHD.2020.012219
Received 18 June 2020; Accepted 30 July 2020; Issue published 07 September 2020
Abstract
Objectives: (1) To measure the global shift in the metabolome in
hypoxemic versus non-hypoxemic infants with congenital heart disease; (2) To
identify metabolites and metabolic pathways that are altered in hypoxemia.
Study
Design: Analysis of serum samples obtained prior to cardiopulmonary bypass
from 82 infants ≤120 days old with congenital heart disease requiring surgery
at Children’s Hospital Colorado. Infants were divided into groups based on preoperative oxygen saturations: non-hypoxemic (>92%), mild hypoxemia
(85–92%), and severe hypoxemia (<85%). Tandem mass spectrometry was used
to analyze 165 targeted metabolites. Partial least squares discriminant analysis and
t-tests were used to determine differences among metabolic profiles and individual
metabolites respectively.
Results: The broad metabolic fingerprint of neonates or
older infants did not vary by degree of hypoxemia. There were 12 individual
metabolites that differed between hypoxemic and non-hypoxemic neonates,
including lower methylmalonic acid (
p = 2.44 × 10
–4
), glutamate (
p = 0.001),
and hypoxanthine (
p = 0.003), and higher thymine (
p = 8.67 × 10
–4
) and myo-inositol (
p = 0.014) seen in hypoxemic neonates. Individual metabolites did not vary
significantly between older infants with or without hypoxemia.
Conclusions: We
did not find evidence supporting global metabolic changes associated with cyanotic congenital heart disease in neonates or older infants. However, specific metabolites did discriminate between hypoxemic and non-hypoxemic neonates. These
include methylmalonic acid, as well as several metabolites known to change in
hypoxia-reoxygenation states (hypoxanthine) and chronic hypoxemic states
(glutamate, thymine, myo-inositol) and may represent specific metabolic changes
triggered by hypoxemia among neonates with cyanotic congenital heart disease.
Keywords
Cite This Article
Pagano, E., Frank, B., Jaggers, J., Twite, M., Urban, T. T. et al. (2020). Alterations in Metabolites Associated with Hypoxemia in Neonates and Infants with Congenital Heart Disease.
Congenital Heart Disease, 15(4), 251–265. https://doi.org/10.32604/CHD.2020.012219